TY  - JOUR
AU  - Miljković, Đorđe
AU  - Poljarević, Jelena
AU  - Petkovic, Filip
AU  - Blazevski, Jana
AU  - Momčilović, Miljana
AU  - Nikolic, Ivana
AU  - Saksida, Tamara
AU  - Stošić-Grujičić, Stanislava D.
AU  - Grgurić-Šipka, Sanja
AU  - Sabo, Tibor
PY  - 2012
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/1258
AB  - We have recently reported that a novel octahedral Pt(IV) complex with di-n-propyl-(S,S)-ethylenediamine-N,N'-di-2-(3-cyclohexyl)propanoato ligand has a potent cytotoxic effect on glioma, melanoma and fibrosarcoma cell lines. In this work, we investigated the influence of the Pt(IV) compound on immune cells. We determined its effect on the viability of spleen cells and lymph node cells and on their capability to produce interferon (IFN)-gamma and interleukin (IL)-17. Also, we researched the compound's impact on peritoneal macrophages and generation of NO in these cells. Our results show that the complex has limited influence on cell viability of immune cells, but profound inhibitory effect on the production of examined immune mediators. These results are valuable as they show that the novel Pt(IV) complex applied in concentrations which are effective against tumor cells do not affect immune cell viability. Moreover, they also imply that the complex has immunomodulatory properties. (C) 2011 Elsevier Masson SAS. All rights reserved.
PB  - Elsevier France-Editions Scientifiques Medicales Elsevier, Paris
T2  - European Journal of Medicinal Chemistry
T1  - Novel octahedral Pt(IV) complex with di-n-propyl-(S,S)-ethylenediamine-N,N '-di-2-(3-cyclohexyl)propanoato ligand exerts potent immunomodulatory effects
VL  - 47
SP  - 194
EP  - 201
DO  - 10.1016/j.ejmech.2011.10.042
ER  - 

@article{
author = "Miljković, Đorđe and Poljarević, Jelena and Petkovic, Filip and Blazevski, Jana and Momčilović, Miljana and Nikolic, Ivana and Saksida, Tamara and Stošić-Grujičić, Stanislava D. and Grgurić-Šipka, Sanja and Sabo, Tibor",
year = "2012",
abstract = "We have recently reported that a novel octahedral Pt(IV) complex with di-n-propyl-(S,S)-ethylenediamine-N,N'-di-2-(3-cyclohexyl)propanoato ligand has a potent cytotoxic effect on glioma, melanoma and fibrosarcoma cell lines. In this work, we investigated the influence of the Pt(IV) compound on immune cells. We determined its effect on the viability of spleen cells and lymph node cells and on their capability to produce interferon (IFN)-gamma and interleukin (IL)-17. Also, we researched the compound's impact on peritoneal macrophages and generation of NO in these cells. Our results show that the complex has limited influence on cell viability of immune cells, but profound inhibitory effect on the production of examined immune mediators. These results are valuable as they show that the novel Pt(IV) complex applied in concentrations which are effective against tumor cells do not affect immune cell viability. Moreover, they also imply that the complex has immunomodulatory properties. (C) 2011 Elsevier Masson SAS. All rights reserved.",
publisher = "Elsevier France-Editions Scientifiques Medicales Elsevier, Paris",
journal = "European Journal of Medicinal Chemistry",
title = "Novel octahedral Pt(IV) complex with di-n-propyl-(S,S)-ethylenediamine-N,N '-di-2-(3-cyclohexyl)propanoato ligand exerts potent immunomodulatory effects",
volume = "47",
pages = "194-201",
doi = "10.1016/j.ejmech.2011.10.042"
}

Miljković, Đ., Poljarević, J., Petkovic, F., Blazevski, J., Momčilović, M., Nikolic, I., Saksida, T., Stošić-Grujičić, S. D., Grgurić-Šipka, S.,& Sabo, T.. (2012). Novel octahedral Pt(IV) complex with di-n-propyl-(S,S)-ethylenediamine-N,N '-di-2-(3-cyclohexyl)propanoato ligand exerts potent immunomodulatory effects. in European Journal of Medicinal Chemistry
Elsevier France-Editions Scientifiques Medicales Elsevier, Paris., 47, 194-201.
https://doi.org/10.1016/j.ejmech.2011.10.042

Miljković Đ, Poljarević J, Petkovic F, Blazevski J, Momčilović M, Nikolic I, Saksida T, Stošić-Grujičić SD, Grgurić-Šipka S, Sabo T. Novel octahedral Pt(IV) complex with di-n-propyl-(S,S)-ethylenediamine-N,N '-di-2-(3-cyclohexyl)propanoato ligand exerts potent immunomodulatory effects. in European Journal of Medicinal Chemistry. 2012;47:194-201.
doi:10.1016/j.ejmech.2011.10.042 .

Miljković, Đorđe, Poljarević, Jelena, Petkovic, Filip, Blazevski, Jana, Momčilović, Miljana, Nikolic, Ivana, Saksida, Tamara, Stošić-Grujičić, Stanislava D., Grgurić-Šipka, Sanja, Sabo, Tibor, "Novel octahedral Pt(IV) complex with di-n-propyl-(S,S)-ethylenediamine-N,N '-di-2-(3-cyclohexyl)propanoato ligand exerts potent immunomodulatory effects" in European Journal of Medicinal Chemistry, 47 (2012):194-201,
https://doi.org/10.1016/j.ejmech.2011.10.042 . .

TY  - JOUR
AU  - Pešić, Milica
AU  - Banković, Jasna
AU  - Aljančić, Ivana
AU  - Todorović, Nina
AU  - Jadranin, Milka
AU  - Vajs, Vlatka
AU  - Tešević, Vele
AU  - Vučković, Ivan M.
AU  - Momčilović, Miljana
AU  - Marković, Ivanka
AU  - Tanić, Nikola
AU  - Ruzdijic, Sabera
PY  - 2011
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/1233
AB  - Jatrophane diterpenes were shown to be inhibitors of P-glycoprotein (P-gp). There are also evidences on their microtubule-interacting activity in cancer cells. We evaluated new anti-cancer characteristics of two jatrophane type compounds from Euphorbia dendroides. For that purpose, the model system of sensitive non-small cell lung cancer cell line (NCI-H460) and its resistant counterpart (NCI-H460/R) was used. Although both jatrophanes showed inhibitory effect on cancer cell growth, they were non-toxic for peripheral blood mononuclear cells (PBMC). We examined their effects in combination with paclitaxel (PTX), a well-known mitotic spindle interacting chemotherapeutic. Jatrophanes overcome PTX resistance in concentration-dependent manner in MDR cancer cell line (NCI-H460/R). We observed that this synergistic effect is not caused merely by P-gp inhibition. In combination with PTX, jatrophanes induce cell killing and change cell cycle distribution leading to G2/M arrest. Furthermore, they exert an anti-angiogenic effect by decreasing the vascular endothelial growth factor (VEGF) secretion. The reduction of the level of mdr1 mRNA expression in sensitive cells, suggests that these compounds could not contribute to the development of resistance. In conclusion, present study provides a rational basis for the new cancer treatment approach with jatrophanes that are non-toxic to normal cells and have new favorable anti-cancer characteristics. (C) 2011 Elsevier Ltd. All rights reserved.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Food and Chemical Toxicology
T1  - New anti-cancer characteristics of jatrophane diterpenes from Euphorbia dendroides
VL  - 49
IS  - 12
SP  - 3165
EP  - 3173
DO  - 10.1016/j.fct.2011.09.035
ER  - 

@article{
author = "Pešić, Milica and Banković, Jasna and Aljančić, Ivana and Todorović, Nina and Jadranin, Milka and Vajs, Vlatka and Tešević, Vele and Vučković, Ivan M. and Momčilović, Miljana and Marković, Ivanka and Tanić, Nikola and Ruzdijic, Sabera",
year = "2011",
abstract = "Jatrophane diterpenes were shown to be inhibitors of P-glycoprotein (P-gp). There are also evidences on their microtubule-interacting activity in cancer cells. We evaluated new anti-cancer characteristics of two jatrophane type compounds from Euphorbia dendroides. For that purpose, the model system of sensitive non-small cell lung cancer cell line (NCI-H460) and its resistant counterpart (NCI-H460/R) was used. Although both jatrophanes showed inhibitory effect on cancer cell growth, they were non-toxic for peripheral blood mononuclear cells (PBMC). We examined their effects in combination with paclitaxel (PTX), a well-known mitotic spindle interacting chemotherapeutic. Jatrophanes overcome PTX resistance in concentration-dependent manner in MDR cancer cell line (NCI-H460/R). We observed that this synergistic effect is not caused merely by P-gp inhibition. In combination with PTX, jatrophanes induce cell killing and change cell cycle distribution leading to G2/M arrest. Furthermore, they exert an anti-angiogenic effect by decreasing the vascular endothelial growth factor (VEGF) secretion. The reduction of the level of mdr1 mRNA expression in sensitive cells, suggests that these compounds could not contribute to the development of resistance. In conclusion, present study provides a rational basis for the new cancer treatment approach with jatrophanes that are non-toxic to normal cells and have new favorable anti-cancer characteristics. (C) 2011 Elsevier Ltd. All rights reserved.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Food and Chemical Toxicology",
title = "New anti-cancer characteristics of jatrophane diterpenes from Euphorbia dendroides",
volume = "49",
number = "12",
pages = "3165-3173",
doi = "10.1016/j.fct.2011.09.035"
}

Pešić, M., Banković, J., Aljančić, I., Todorović, N., Jadranin, M., Vajs, V., Tešević, V., Vučković, I. M., Momčilović, M., Marković, I., Tanić, N.,& Ruzdijic, S.. (2011). New anti-cancer characteristics of jatrophane diterpenes from Euphorbia dendroides. in Food and Chemical Toxicology
Pergamon-Elsevier Science Ltd, Oxford., 49(12), 3165-3173.
https://doi.org/10.1016/j.fct.2011.09.035

Pešić M, Banković J, Aljančić I, Todorović N, Jadranin M, Vajs V, Tešević V, Vučković IM, Momčilović M, Marković I, Tanić N, Ruzdijic S. New anti-cancer characteristics of jatrophane diterpenes from Euphorbia dendroides. in Food and Chemical Toxicology. 2011;49(12):3165-3173.
doi:10.1016/j.fct.2011.09.035 .

Pešić, Milica, Banković, Jasna, Aljančić, Ivana, Todorović, Nina, Jadranin, Milka, Vajs, Vlatka, Tešević, Vele, Vučković, Ivan M., Momčilović, Miljana, Marković, Ivanka, Tanić, Nikola, Ruzdijic, Sabera, "New anti-cancer characteristics of jatrophane diterpenes from Euphorbia dendroides" in Food and Chemical Toxicology, 49, no. 12 (2011):3165-3173,
https://doi.org/10.1016/j.fct.2011.09.035 . .

TY  - JOUR
AU  - Markovic, M
AU  - Knezevic, N
AU  - Momčilović, Miljana
AU  - Grgurić-Šipka, Sanja
AU  - Harhaji-Trajkovic, Ljubica
AU  - Trajković, Vladimir S.
AU  - Stojkovic, MM
AU  - Sabo, Tibor
AU  - Miljković, Đorđe
PY  - 2005
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/718
AB  - There has been a continuing effort for the discovery of novel platinum(IV)-based antitumor compounds with better therapeutic performances than cisplatin. In the present work, the anticancer action of recently synthesized Pt(IV)-based complex [Pt(HPxSC)Cl-3] was investigated using rat and human astrocytoma cell lines C6 and U251. [Pt(HPxSC)Cl-3] markedly reduced the number of cultured astrocytoma Cells (IC50, 80 mu M), as determined by crystal violet assay. The Pt(IV) complex induced apoptotic death of tumor cells, as flow cytometry analysis of the propidium iodide-stained cellular DNA revealed approx. 30% of hypodiploid cells in [Pt(HPxSC)Cl-3]-treated astrocytoma cell cultures. On the other hand, [Pt(HPxSC)Cl-3] at 200 mu M did not affect the viability of rat primary astrocytes, unlike the established anticancer drug cisplatin, which displayed high toxicity toward both astrocytoma cells (IC50, 15 mu M) and primary astrocytes (IC50, 20 mu M). Moreover, [Pt(HPxSC)Cl-3] at 100 mu M did not interfere with the ability of rat peritoneal macrophages to produce important antitumor molecules nitric oxide and tumor necrosis factor-a. Finally, we assessed the ability of [Pt(HPxSC)Cl-3] to restrain growth of some bacterial and yeast strains, but it showed rather limited antimicrobial activity. (c) 2005 Elsevier B.V. All rights reserved.
PB  - Elsevier Science Bv, Amsterdam
T2  - European Journal of Pharmacology
T1  - [Pt(HPxSC)Cl-3], a novel platinum(IV) compound with anticancer properties
VL  - 517
IS  - 1-2
SP  - 28
EP  - 34
DO  - 10.1016/j.ejphar.2005.05.038
ER  - 

@article{
author = "Markovic, M and Knezevic, N and Momčilović, Miljana and Grgurić-Šipka, Sanja and Harhaji-Trajkovic, Ljubica and Trajković, Vladimir S. and Stojkovic, MM and Sabo, Tibor and Miljković, Đorđe",
year = "2005",
abstract = "There has been a continuing effort for the discovery of novel platinum(IV)-based antitumor compounds with better therapeutic performances than cisplatin. In the present work, the anticancer action of recently synthesized Pt(IV)-based complex [Pt(HPxSC)Cl-3] was investigated using rat and human astrocytoma cell lines C6 and U251. [Pt(HPxSC)Cl-3] markedly reduced the number of cultured astrocytoma Cells (IC50, 80 mu M), as determined by crystal violet assay. The Pt(IV) complex induced apoptotic death of tumor cells, as flow cytometry analysis of the propidium iodide-stained cellular DNA revealed approx. 30% of hypodiploid cells in [Pt(HPxSC)Cl-3]-treated astrocytoma cell cultures. On the other hand, [Pt(HPxSC)Cl-3] at 200 mu M did not affect the viability of rat primary astrocytes, unlike the established anticancer drug cisplatin, which displayed high toxicity toward both astrocytoma cells (IC50, 15 mu M) and primary astrocytes (IC50, 20 mu M). Moreover, [Pt(HPxSC)Cl-3] at 100 mu M did not interfere with the ability of rat peritoneal macrophages to produce important antitumor molecules nitric oxide and tumor necrosis factor-a. Finally, we assessed the ability of [Pt(HPxSC)Cl-3] to restrain growth of some bacterial and yeast strains, but it showed rather limited antimicrobial activity. (c) 2005 Elsevier B.V. All rights reserved.",
publisher = "Elsevier Science Bv, Amsterdam",
journal = "European Journal of Pharmacology",
title = "[Pt(HPxSC)Cl-3], a novel platinum(IV) compound with anticancer properties",
volume = "517",
number = "1-2",
pages = "28-34",
doi = "10.1016/j.ejphar.2005.05.038"
}

Markovic, M., Knezevic, N., Momčilović, M., Grgurić-Šipka, S., Harhaji-Trajkovic, L., Trajković, V. S., Stojkovic, M., Sabo, T.,& Miljković, Đ.. (2005). [Pt(HPxSC)Cl-3], a novel platinum(IV) compound with anticancer properties. in European Journal of Pharmacology
Elsevier Science Bv, Amsterdam., 517(1-2), 28-34.
https://doi.org/10.1016/j.ejphar.2005.05.038

Markovic M, Knezevic N, Momčilović M, Grgurić-Šipka S, Harhaji-Trajkovic L, Trajković VS, Stojkovic M, Sabo T, Miljković Đ. [Pt(HPxSC)Cl-3], a novel platinum(IV) compound with anticancer properties. in European Journal of Pharmacology. 2005;517(1-2):28-34.
doi:10.1016/j.ejphar.2005.05.038 .

Markovic, M, Knezevic, N, Momčilović, Miljana, Grgurić-Šipka, Sanja, Harhaji-Trajkovic, Ljubica, Trajković, Vladimir S., Stojkovic, MM, Sabo, Tibor, Miljković, Đorđe, "[Pt(HPxSC)Cl-3], a novel platinum(IV) compound with anticancer properties" in European Journal of Pharmacology, 517, no. 1-2 (2005):28-34,
https://doi.org/10.1016/j.ejphar.2005.05.038 . .

TY  - JOUR
AU  - Kaludjerovic, GN
AU  - Miljković, Đorđe
AU  - Momčilović, Miljana
AU  - Djinovic, VM
AU  - Stojkovic, MM
AU  - Sabo, Tibor
AU  - Trajković, Vladimir S.
PY  - 2005
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/719
AB  - The anticancer activity of platinum complexes has been known since the discovery of classical Pt(II)-based drug cisplatin. However, Pt(IV) complexes have greater inertness than corresponding Pt(II) complexes, thus allowing the oral administration and reducing the toxicity associated with platinum-based chemotherapy. Here, we describe the in vitro antitumor activity of some novel Pt(IV)-based agents against mouse fibrosarcoma L929 cells and human astrocytoma U251 cells. The cytotoxicity of 2 Pt(IV) complexes with bidentate ethylenediamine-N,N'-di-3-propanoato esters was found to be markedly higher than that of their Pt(II) counterparts and comparable to the antitumor action of cisplatin. In contrast to cisplatin, which caused oxidative stress-independent apoptotic cell death of tumor cells, these Pt(IV) complexes induced oxygen radical-mediated tumor cell necrosis. Importantly, the cytotoxic action of novel Pt(IV) complexes was markedly more rapid than that of cisplatin, indicating their potential usefulness in anticancer therapy. (C) 2005 Wiley-Liss, Inc.
PB  - Wiley, Hoboken
T2  - International Journal of Cancer
T1  - Novel platinum(IV) complexes induce rapid tumor cell death in vitro
VL  - 116
IS  - 3
SP  - 479
EP  - 486
DO  - 10.1002/ijc.21080
ER  - 

@article{
author = "Kaludjerovic, GN and Miljković, Đorđe and Momčilović, Miljana and Djinovic, VM and Stojkovic, MM and Sabo, Tibor and Trajković, Vladimir S.",
year = "2005",
abstract = "The anticancer activity of platinum complexes has been known since the discovery of classical Pt(II)-based drug cisplatin. However, Pt(IV) complexes have greater inertness than corresponding Pt(II) complexes, thus allowing the oral administration and reducing the toxicity associated with platinum-based chemotherapy. Here, we describe the in vitro antitumor activity of some novel Pt(IV)-based agents against mouse fibrosarcoma L929 cells and human astrocytoma U251 cells. The cytotoxicity of 2 Pt(IV) complexes with bidentate ethylenediamine-N,N'-di-3-propanoato esters was found to be markedly higher than that of their Pt(II) counterparts and comparable to the antitumor action of cisplatin. In contrast to cisplatin, which caused oxidative stress-independent apoptotic cell death of tumor cells, these Pt(IV) complexes induced oxygen radical-mediated tumor cell necrosis. Importantly, the cytotoxic action of novel Pt(IV) complexes was markedly more rapid than that of cisplatin, indicating their potential usefulness in anticancer therapy. (C) 2005 Wiley-Liss, Inc.",
publisher = "Wiley, Hoboken",
journal = "International Journal of Cancer",
title = "Novel platinum(IV) complexes induce rapid tumor cell death in vitro",
volume = "116",
number = "3",
pages = "479-486",
doi = "10.1002/ijc.21080"
}

Kaludjerovic, G., Miljković, Đ., Momčilović, M., Djinovic, V., Stojkovic, M., Sabo, T.,& Trajković, V. S.. (2005). Novel platinum(IV) complexes induce rapid tumor cell death in vitro. in International Journal of Cancer
Wiley, Hoboken., 116(3), 479-486.
https://doi.org/10.1002/ijc.21080

Kaludjerovic G, Miljković Đ, Momčilović M, Djinovic V, Stojkovic M, Sabo T, Trajković VS. Novel platinum(IV) complexes induce rapid tumor cell death in vitro. in International Journal of Cancer. 2005;116(3):479-486.
doi:10.1002/ijc.21080 .

Kaludjerovic, GN, Miljković, Đorđe, Momčilović, Miljana, Djinovic, VM, Stojkovic, MM, Sabo, Tibor, Trajković, Vladimir S., "Novel platinum(IV) complexes induce rapid tumor cell death in vitro" in International Journal of Cancer, 116, no. 3 (2005):479-486,
https://doi.org/10.1002/ijc.21080 . .

TY  - JOUR
AU  - Djinovic, V
AU  - Momčilović, Miljana
AU  - Grgurić-Šipka, Sanja
AU  - Trajković, Vladimir S.
AU  - Stojkovic, MM
AU  - Miljković, Đorđe
AU  - Sabo, Tibor
PY  - 2004
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/672
AB  - A novel class of ruthenium (111) complexes of formulas K[Ru(sar)(2)Cl-2] - 1/2HO and K-2[Ru(dmgly)Cl-4] . 1/2H(2)O, containing biden2 tate chelates N-methylglycine (sarcosine, sar) or N,N-dimethylglycine (dnigly) and additional chloro ligands were synthesized. The complexes have been obtained by direct reaction of ruthenium(III) chloride with corresponding bidentate ligand followed by addition of base (KOH). These new complexes were characterized by elemental analysis, IR and electronic absorption spectroscopy. As astrocytomas, the most common of all brain tumors, are still very difficult to treat, we examined the influence of newly synthesized ruthenium-based complexes, as well as the earlier synthesized analogue platinum(IV) complexes [Pt(dmglY)(2)Cl-2], [Pt(sar)(2)Br-2] and [Pt(dmgly)(2)Br-2] on rat astrocytoma C6 cells in vitro. Among these complexes only K-2[Ru(dmglY)Cl-4].2H(2)O and [Pt(dMgIY)(2)Br-2] markedly inhibited the viability of non-confluent C6 cells. Furthermore, only complex K-2[Ru(dmgly)Cl4] .2H20 was able to reduce viability in confluent C6 cultures. Importantly, this complex was not toxic to primary rat astrocytes or macrophages. Having in mind that appropriate chemotherapy should be effective against tumor cells without harming normal tissues, complex K,[Ru(dmglY)Cl-4] - 2H(2)O could be a promising agent for developing therapeutics against astrocytomas. (C) 2004 Elsevier Inc. All rights reserved.
PB  - Elsevier Science Inc, New York
T2  - Journal of Inorganic Biochemistry
T1  - Novel ruthenium complex K-2[Ru(dmgly)Cl-4] center dot 2H(2)O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes
VL  - 98
IS  - 12
SP  - 2168
EP  - 2173
DO  - 10.1016/j.jinorgbio.2004.10.007
ER  - 

@article{
author = "Djinovic, V and Momčilović, Miljana and Grgurić-Šipka, Sanja and Trajković, Vladimir S. and Stojkovic, MM and Miljković, Đorđe and Sabo, Tibor",
year = "2004",
abstract = "A novel class of ruthenium (111) complexes of formulas K[Ru(sar)(2)Cl-2] - 1/2HO and K-2[Ru(dmgly)Cl-4] . 1/2H(2)O, containing biden2 tate chelates N-methylglycine (sarcosine, sar) or N,N-dimethylglycine (dnigly) and additional chloro ligands were synthesized. The complexes have been obtained by direct reaction of ruthenium(III) chloride with corresponding bidentate ligand followed by addition of base (KOH). These new complexes were characterized by elemental analysis, IR and electronic absorption spectroscopy. As astrocytomas, the most common of all brain tumors, are still very difficult to treat, we examined the influence of newly synthesized ruthenium-based complexes, as well as the earlier synthesized analogue platinum(IV) complexes [Pt(dmglY)(2)Cl-2], [Pt(sar)(2)Br-2] and [Pt(dmgly)(2)Br-2] on rat astrocytoma C6 cells in vitro. Among these complexes only K-2[Ru(dmglY)Cl-4].2H(2)O and [Pt(dMgIY)(2)Br-2] markedly inhibited the viability of non-confluent C6 cells. Furthermore, only complex K-2[Ru(dmgly)Cl4] .2H20 was able to reduce viability in confluent C6 cultures. Importantly, this complex was not toxic to primary rat astrocytes or macrophages. Having in mind that appropriate chemotherapy should be effective against tumor cells without harming normal tissues, complex K,[Ru(dmglY)Cl-4] - 2H(2)O could be a promising agent for developing therapeutics against astrocytomas. (C) 2004 Elsevier Inc. All rights reserved.",
publisher = "Elsevier Science Inc, New York",
journal = "Journal of Inorganic Biochemistry",
title = "Novel ruthenium complex K-2[Ru(dmgly)Cl-4] center dot 2H(2)O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes",
volume = "98",
number = "12",
pages = "2168-2173",
doi = "10.1016/j.jinorgbio.2004.10.007"
}

Djinovic, V., Momčilović, M., Grgurić-Šipka, S., Trajković, V. S., Stojkovic, M., Miljković, Đ.,& Sabo, T.. (2004). Novel ruthenium complex K-2[Ru(dmgly)Cl-4] center dot 2H(2)O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes. in Journal of Inorganic Biochemistry
Elsevier Science Inc, New York., 98(12), 2168-2173.
https://doi.org/10.1016/j.jinorgbio.2004.10.007

Djinovic V, Momčilović M, Grgurić-Šipka S, Trajković VS, Stojkovic M, Miljković Đ, Sabo T. Novel ruthenium complex K-2[Ru(dmgly)Cl-4] center dot 2H(2)O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes. in Journal of Inorganic Biochemistry. 2004;98(12):2168-2173.
doi:10.1016/j.jinorgbio.2004.10.007 .

Djinovic, V, Momčilović, Miljana, Grgurić-Šipka, Sanja, Trajković, Vladimir S., Stojkovic, MM, Miljković, Đorđe, Sabo, Tibor, "Novel ruthenium complex K-2[Ru(dmgly)Cl-4] center dot 2H(2)O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes" in Journal of Inorganic Biochemistry, 98, no. 12 (2004):2168-2173,
https://doi.org/10.1016/j.jinorgbio.2004.10.007 . .